A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity.
A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity.
复制标题
DOI：
10.1038/s41541-023-00753-4
复制
发表时间：
2023-10-20
期刊：
影响因子：
9.2
通讯作者：
中科院分区：
文献类型：
--
作者：
先前报道了一种具有修饰的病毒转录调控序列和缺失开放阅读框3、6、7和8的减毒SARS-CoV-2病毒（SARS 3678），以保护仓鼠免受SARS-CoV-2感染和传播。在这里，我们报告说，单剂量鼻内接种SARS 3678保护K18-hACE 2小鼠野生型或变异SARS-CoV-2的挑战。与野生型病毒感染相比，E13678疫苗接种诱导等同或更高水平的肺和全身T细胞、B细胞、伊加和IgG应答。结果表明，SARS 3678是一种有吸引力的粘膜疫苗候选物，可增强对SARS-CoV-2的肺部免疫。
An attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge. Compared with wild-type virus infection, the ∆3678 vaccination induces equivalent or higher levels of lung and systemic T cell, B cell, IgA, and IgG responses. The results suggest ∆3678 as an attractive mucosal vaccine candidate to boost pulmonary immunity against SARS-CoV-2.